# Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries

Study · id `cardio:ct-nct03080935` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03080935](<https://clinicaltrials.gov/study/NCT03080935>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03080935

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 1600 participants.

## Technical summary

Registry record NCT03080935. Allocation not applicable; no masking; primary purpose treatment. Start 2017-03-13 (actual); primary completion 2022-03-04 (actual). Results posted on 2023-01-11.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1600 participants (enrolled count; ClinicalTrials.gov record NCT03080935, source copy `cardio:ctgov-nct03080935-2024-05-29`, retrieved 2026-10-31)
- Started: 2017-03-13 (actual) (ClinicalTrials.gov record NCT03080935, source copy `cardio:ctgov-nct03080935-2024-05-29`, retrieved 2026-10-31)
- Primary completion: 2022-03-04 (actual) (ClinicalTrials.gov record NCT03080935, source copy `cardio:ctgov-nct03080935-2024-05-29`, retrieved 2026-10-31)
- Completion: 2022-03-04 (actual) (ClinicalTrials.gov record NCT03080935, source copy `cardio:ctgov-nct03080935-2024-05-29`, retrieved 2026-10-31)
- Results first posted: 2023-01-11 (ClinicalTrials.gov record NCT03080935, source copy `cardio:ctgov-nct03080935-2024-05-29`, retrieved 2026-10-31)
- Countries: Belgium; Denmark; France; Germany; Italy; Portugal; Sweden (ClinicalTrials.gov record NCT03080935, source copy `cardio:ctgov-nct03080935-2024-05-29`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03080935-2024-05-29`, retrieved 2026-10-31)

## The registry's words

- Brief title: Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries
- Condition: Dyslipidemia
- Intervention (Drug): Evolocumab
- Lead sponsor: Amgen
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry intervention name matches this record: Evolocumab (`cardio:evolocumab`)
- Registry lists this organization as the lead sponsor: Amgen (`cardio:org-amgen`)

## Provenance

Content hash: 532791421e4531fa0d8e999c1a285677ba9aaa12f88ba66491fb5d7627fdc6c3
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
